FR13C0030I1 - Compositions pour le traitement de troubles gastrointestinaux - Google Patents

Compositions pour le traitement de troubles gastrointestinaux

Info

Publication number
FR13C0030I1
FR13C0030I1 FR13C0030C FR13C0030C FR13C0030I1 FR 13C0030 I1 FR13C0030 I1 FR 13C0030I1 FR 13C0030 C FR13C0030 C FR 13C0030C FR 13C0030 C FR13C0030 C FR 13C0030C FR 13C0030 I1 FR13C0030 I1 FR 13C0030I1
Authority
FR
France
Prior art keywords
compositions
treatment
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0030C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0030(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of FR13C0030I1 publication Critical patent/FR13C0030I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FR13C0030C 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux Active FR13C0030I1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
EP04706011A EP1594517B1 (fr) 2003-01-28 2004-01-28 Compositions pour le traitement de troubles gastro-intestinaux
EP07011869A EP1911763B1 (fr) 2003-01-28 2004-01-28 Compositions pour le traitement de troubles gastrointestinaux

Publications (1)

Publication Number Publication Date
FR13C0030I1 true FR13C0030I1 (fr) 2013-07-05

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0030C Active FR13C0030I1 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux
FR13C0029C Active FR13C0029I2 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0029C Active FR13C0029I2 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux

Country Status (29)

Country Link
US (3) US20040266989A1 (fr)
EP (3) EP1594517B1 (fr)
JP (3) JP4584911B2 (fr)
KR (2) KR101227626B1 (fr)
CN (2) CN101787073B (fr)
AT (2) ATE477268T1 (fr)
AU (2) AU2004210161B2 (fr)
BE (1) BE2013C032I2 (fr)
BR (2) BRPI0407071B8 (fr)
CA (1) CA2514507C (fr)
CY (5) CY1110905T1 (fr)
DE (2) DE602004007105T2 (fr)
DK (3) DK1594517T3 (fr)
ES (3) ES2387848T3 (fr)
FR (2) FR13C0030I1 (fr)
HK (1) HK1078768A1 (fr)
HU (1) HUS1300022I1 (fr)
IL (2) IL169863A (fr)
LT (1) LTC1594517I2 (fr)
LU (2) LU92201I2 (fr)
MX (1) MXPA05008097A (fr)
NL (1) NL300593I2 (fr)
NO (2) NO334112B1 (fr)
NZ (2) NZ541595A (fr)
PT (3) PT1911763E (fr)
RU (2) RU2543350C2 (fr)
SG (2) SG168407A1 (fr)
SI (3) SI1594517T1 (fr)
WO (1) WO2004069165A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006651B1 (ru) 2001-03-29 2006-02-24 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазного рецептора для лечения тканевого воспаления и канцерогенеза
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1594517B1 (fr) 2003-01-28 2007-06-20 Microbia, Inc. Compositions pour le traitement de troubles gastro-intestinaux
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
EP3342420A1 (fr) 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Procédé et compositions de traitement des troubles gastro-intestinaux
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
JPWO2006046746A1 (ja) * 2004-10-26 2008-05-22 味の素株式会社 内臓痛予防・治療剤
EP1940441A4 (fr) * 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc Compositions et methodes de traitement de troubles gastro-intestinaux
CN101287464A (zh) 2005-09-29 2008-10-15 科学研究和应用咨询股份公司 用于刺激胃肠运动性的组合物和方法
US20090305993A1 (en) * 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
EP2129683A4 (fr) * 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc Procedes et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
MX2009011898A (es) * 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3239170B1 (fr) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2726913C (fr) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010005515A2 (fr) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Procédés d’expression de protéines
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
MX2020005326A (es) * 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
WO2010059733A1 (fr) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Forme cristalline de la linaclotide
CA2745694C (fr) * 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et methode d'utilisation
WO2010115916A1 (fr) 2009-04-10 2010-10-14 F. Hoffmann-La Roche Ag Procédé d'isolement d'un peptide thérapeutique
MX2012001660A (es) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
EP2464373A1 (fr) 2009-08-13 2012-06-20 Ironwood Pharmaceuticals, Inc. Procédé de modulation de l'effet pharmacodynamique d'agonistes des récepteurs de guanylate cyclase administrés par voie orale
WO2011057272A1 (fr) * 2009-11-09 2011-05-12 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
US8735360B2 (en) 2009-12-07 2014-05-27 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011103311A2 (fr) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Traitements de troubles gastro-intestinaux
WO2011145062A1 (fr) 2010-05-21 2011-11-24 Link Research & Grants Corporation Traitement des acouphènes et de dysfonctions auditives apparentées
EP2605786A4 (fr) * 2010-06-09 2014-03-12 Combimab Inc Peptides thérapeutiques
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
EP2621509A4 (fr) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9650417B2 (en) 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155114A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Nouveaux dérivés d'uroguanyline et leur utilisation pour le traitement des troubles gastro-intestinaux
WO2012170766A1 (fr) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
EP2776055B1 (fr) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Traitements pour des troubles gastro-intestinaux
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
EP2950803A1 (fr) 2013-01-30 2015-12-09 Sandoz AG Forme cristalline de linaclotide
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
IL280864B2 (en) 2013-08-09 2024-03-01 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
HUE061954T2 (hu) * 2015-05-01 2023-09-28 Ironwood Pharmaceuticals Inc Vastagbél tisztítására és gyomor-bélrendszeri rendellenességek kezelésére szolgáló készítmények
EP3430056A4 (fr) * 2016-03-15 2019-11-20 The Regents of the University of California Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine alpha 8 beta 1
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
EP3870263A4 (fr) * 2018-10-23 2022-08-03 ABK Biomedical Incorporated Dispositif d'administration
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
WO2023144292A1 (fr) 2022-01-28 2023-08-03 Fresenius Kabi Ipsum S.R.L. Procédé de préparation de linaclotide

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US258687A (en) * 1882-05-30 Grain-binder
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US232013A (en) * 1880-09-07 Henry h
US32684A (en) * 1861-07-02 Stump-extkactob
US266989A (en) * 1882-11-07 Automatic fire
US73628A (en) * 1868-01-21 mitchell
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (fr) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (fr) 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
PL171920B1 (pl) * 1991-12-02 1997-06-30 Cor Therapeutics Inc Sposób wytwarzania nowego, hamujacego PDGF-R polipeptydy immunoglobulinowego PL
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
EP0625162B1 (fr) 1991-12-30 1998-05-13 Neurex Corporation Procedes servant a induire l'analgesie et a favoriser l'analgesie par opiaces
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
WO1994015587A2 (fr) 1993-01-06 1994-07-21 Kinerton Limited Conjugues moleculaires ioniques de polyesters biodegradables et de polypeptides biologiquement actifs
US5395490A (en) * 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
US6060037A (en) * 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
AU695166B2 (en) 1995-06-27 1998-08-06 Azur Pharma International Limited Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
ES2236757T3 (es) 1995-11-24 2005-07-16 Glaxosmithkline S.P.A. Derivados de quinolina.
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
IL126422A (en) 1996-04-23 2004-02-19 Kinerton Ltd Biodegradable acidic polylactic polymers and methods for their preparation
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
US6333354B1 (en) 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
ES2222613T3 (es) 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
PT1593387E (pt) 1999-06-23 2009-03-18 Pasteur Institut Composições para o tratamento de desordens comportamentais e deficiências interpessoais.
ATE252915T1 (de) 1999-08-18 2003-11-15 Sod Conseils Rech Applic Formulierung zur verzögerten freisetzung von peptiden
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
WO2001025266A1 (fr) 1999-10-06 2001-04-12 Pharmacia Corporation Uroguanyline, anticancereux intestinal
ATE275402T1 (de) 1999-11-01 2004-09-15 John Rhodes Arzneimittel zur behandlung von darmverstopfung und reizkolon
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU3580001A (en) 2000-03-01 2001-09-12 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
DK1216707T3 (da) 2000-12-22 2005-05-09 Pasteur Institut Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet
CA2435835A1 (fr) 2001-02-02 2002-08-15 Pharmacia Corporation Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
EA006651B1 (ru) * 2001-03-29 2006-02-24 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазного рецептора для лечения тканевого воспаления и канцерогенеза
AU2002311556A1 (en) 2001-03-30 2002-10-15 University Of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
DE10292434D2 (de) * 2001-06-05 2004-07-29 Yueksel Savas Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (fr) 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
EP1531846A4 (fr) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugues de ligand, adaptateur et agent cytotoxique, compositions associees et procedes d'utilisation relatifs
EP1485078B1 (fr) 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran pour le traitement du syndrôme du colon irritable
JP2005531557A (ja) 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
EP1594517B1 (fr) 2003-01-28 2007-06-20 Microbia, Inc. Compositions pour le traitement de troubles gastro-intestinaux
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (fr) 2003-02-10 2010-09-08 Univ Jefferson Utilisation de ligands gcc
EP1940441A4 (fr) 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc Compositions et methodes de traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
AU2004210161A1 (en) 2004-08-19
WO2004069165A2 (fr) 2004-08-19
EP1594517B1 (fr) 2007-06-20
SI1594517T1 (sl) 2007-10-31
PT1594517E (pt) 2007-07-20
FR13C0029I1 (fr) 2013-07-05
US7704947B2 (en) 2010-04-27
BR122018074353B8 (pt) 2023-05-02
ATE477268T1 (de) 2010-08-15
BRPI0407071B8 (pt) 2021-05-25
KR20050106404A (ko) 2005-11-09
AU2009235993A1 (en) 2009-11-26
ES2387848T3 (es) 2012-10-02
SG192300A1 (en) 2013-08-30
NZ570134A (en) 2010-02-26
DK1594517T3 (da) 2007-10-29
JP2006516631A (ja) 2006-07-06
US20110124583A1 (en) 2011-05-26
BRPI0407071B1 (pt) 2019-02-12
SI1911763T1 (sl) 2010-11-30
CY1111058T1 (el) 2015-06-11
EP2246360A1 (fr) 2010-11-03
HUS1300022I1 (hu) 2019-11-28
PT1911763E (pt) 2010-11-18
RU2005127058A (ru) 2006-03-10
NZ541595A (en) 2008-08-29
HK1078768A1 (en) 2006-03-24
RU2763796C2 (ru) 2022-01-11
LU92201I2 (fr) 2013-11-22
RU2008147983A (ru) 2010-06-10
ATE365174T1 (de) 2007-07-15
NO336768B1 (no) 2015-11-02
CY1110905T1 (el) 2015-06-10
SI2246360T1 (sl) 2012-10-30
CN101787073B (zh) 2013-12-25
JP2010222377A (ja) 2010-10-07
BRPI0407071A (pt) 2006-01-24
LU92200I2 (fr) 2024-03-21
LU92200I1 (fr) 2020-06-02
EP1911763A2 (fr) 2008-04-16
AU2009235993B2 (en) 2013-07-04
CY2013022I1 (el) 2020-05-29
NL300593I2 (nl) 2020-04-15
EP2246360B1 (fr) 2012-06-27
NO20053864D0 (no) 2005-08-18
RU2353383C2 (ru) 2009-04-27
CA2514507A1 (fr) 2004-08-19
EP1594517A2 (fr) 2005-11-16
IL221380A0 (en) 2012-09-24
IL169863A (en) 2012-10-31
WO2004069165A3 (fr) 2005-03-17
EP1911763B1 (fr) 2010-08-11
MXPA05008097A (es) 2006-02-08
ES2350123T3 (es) 2011-01-18
NO334112B1 (no) 2013-12-09
NO20053864L (no) 2005-10-26
RU2014153593A (ru) 2016-07-20
DE602004007105D1 (de) 2007-08-02
DK1911763T3 (da) 2010-11-15
CA2514507C (fr) 2012-03-20
ES2285417T3 (es) 2007-11-16
KR101227626B1 (ko) 2013-02-01
DK2246360T3 (da) 2012-08-13
JP5563384B2 (ja) 2014-07-30
US20040266989A1 (en) 2004-12-30
PT2246360E (pt) 2012-08-31
JP4584911B2 (ja) 2010-11-24
CN1795007A (zh) 2006-06-28
CY1113217T1 (el) 2016-04-13
KR101227627B1 (ko) 2013-01-31
FR13C0029I2 (fr) 2024-04-19
EP1911763A3 (fr) 2008-06-25
KR20110114682A (ko) 2011-10-19
CN101787073A (zh) 2010-07-28
AU2004210161B2 (en) 2009-11-26
JP2013116910A (ja) 2013-06-13
NO20130460L (no) 2005-10-26
NL300593I1 (nl) 2015-10-21
JP5748791B2 (ja) 2015-07-15
CN100589839C (zh) 2010-02-17
US20090005534A1 (en) 2009-01-01
EP1594517A4 (fr) 2006-03-29
LTC1594517I2 (lt) 2020-03-10
US8080526B2 (en) 2011-12-20
DE602004007105T2 (de) 2008-02-28
BR122018074353B1 (pt) 2019-07-16
DE602004028678D1 (de) 2010-09-23
SG168407A1 (en) 2011-02-28
CY2013021I1 (el) 2020-05-29
RU2014153593A3 (fr) 2018-08-06
RU2543350C2 (ru) 2015-02-27
BE2013C032I2 (fr) 2023-08-22

Similar Documents

Publication Publication Date Title
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
MA29098B1 (fr) Compositions pour le traitement du vhc
ZA200610055B (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
PT1644021E (pt) Métodos e composições para o tratamento de distúrbios gastrointestinais
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
EP1658072A4 (fr) Composes pour le traitement de maladies neurodegeneratives
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
FR2924593B1 (fr) Plaque osseuse pour le traitement de l'extremite inferieure du cubitus
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
FR2884714B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR2887456B1 (fr) "composition pour le traitement de la dermite estivale"
FR2868312B1 (fr) Patch pour le traitement des levres
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
MA28513B1 (fr) Processus pour la preparation d'inhibiteurs de tryptase
HK1094698A1 (en) Beta-lactams for the treatment of cns disorders
FR2851247B1 (fr) Methodes et compositions pour le traitement de pathologies degeneratives oculaires